清热通下中药对胆管炎大鼠肠屏障保护

,,,,,,(,200032)[]::60SD3,20(A);(B);(C):A-6(interleukin-6,IL-6)-8(interleukin-8,IL-8)(tumornecrosisfactor-,TNF-)C(Creactiveprotein,CRP)(nitricoxide,NO)BC(P0.01),IL-2BC(P0.01);ABC(P0.01):[];;;[]R283.624;R657.45[]A[]1672-1977(2005)03-0211-05ImpactofantipyreticandpurgativeherbsonintestinalmucosalbarrierandinflammatoryresponseintreatmentofacutecholangitisinratsZHANGJing-Zhe,ZHANGXue-Lin,GAOJu,SHENPing,MAEn-Wei,GUHong-Gang,ZHUPei-Ting(InstituteofChineseTraditionalSurgery,ShanghaiUniversityofTraditionalChineseMedicine,Shanghai200032,China)ABSTRACTObjective:Toinvestigatetheeffectsofantipyreticandpurgativeherbsonintestinalmucosalbarrierandinflammatoryresponseinthetreatmentofacutecholangitis.Methods:SixtySDratswererandomlydividedintogroupA(untreatedgroup,acutecholangitiswasinduced,n=20),groupB(treatmentgroup,acutecholangitiswasinducedandtreatedwithantipyreticandpurgativeherbs,n=20)andgroupC(shamoperationgroup,n=20).Atthethirdorfifthdayafteroperation,theratsweresacrificedandsampled.Theserumendotoxin,cytokinesandinflammatorymediatorsweretestedandthenumbersoflabeledbacteriaintheliver,spleenandmesentericlymphnodestranslocatedfromthegutwereassayed.Results:AscomparedwithgroupA,theserumcontentofendotoxin,IL-6,IL-8,TNF-,CRPandNOwassignificantlylowerandthatofIL-2wassignificantlyhigher,andthetranslocatednumbersoflabeledbacteriafromgutwerereducedinbothgroupBandgroupC(P0.01).Conclusion:Antipyreticandpurgativeherbscanplaytherapeuticrolesinthetreatmentofacutebiliarytractinfections,includingtheprotectionofintestinalmucosalbarrierfrombacterialtranslocation,reductionofserumendotoxincontentandregulationofinflammatoryresponse.KEYWORDSantipyreticandpurgativeherbs;cholangitis;cytokines;inflammatorymediatorsJChinIntegrMed,2005,3(3):211-215,,1122005533JChinIntegrMed,May2005,Vol.3,No.3[][](1955-),,,.Correspondenceto:Prof.ZHANGJing-Zhe.E-mail:[e-mail],,,,,,[1]11.1SD60,,225245g,3,20(,)(A)[2],,,,(B),(C),1.21.2.1,,110mg/ml,1.2.2,O111B4(5109cfu/ml),O55B5(5109cfu/ml),1.2.3,;,FMG182,;CPS-2,;-85,Harris;LXJ-,;,Beckman;(nitricoxide,NO),;-6(interleukin-6,IL-6)-8(interleukin-8,IL-8)(tumornecrosisfactor-,TNF-),;ELISA,1.31.3.125mg/kg,,,,,,O111B41ml/kg,,,35,24hO55B57ml/kg1.3.210ml/kg2110ml/kg1,1,4h,210ml/kg21.3.325mg/kg,,,;1.41.4.1IL-2ELISA,ELISAIL-6IL-8TNF-,1.4.2C(Creactiveprotein,CRP)Beckman,NO1.4.31.4.4(),10,10%,0.1ml24h,O55B51.5SPSS22.13CIL-2,A(P0.01),15,IL-2,B2122005533JChinIntegrMed,May2005,Vol.3,No.3A(P0.01),23ATNF-IL-6IL-8,C(P0.01P0.05),15,TNF-IL-6,BA(P0.01);5,ABIL-8,BA(P0.05),22.23ABCRPC(P0.01),A,BA(P0.05),3;5ABCRP,B(P0.01),43ABNOC(P0.01),A,BA(P0.05),3;5ABNO,C,AB,413Tab1Serumcontentofcytokinesineachgrouponthethirdexperimentday(xs)GroupnTNF(ng/L)IL-2(ng/L)IL-6(g/L)IL-8(g/L)GroupA8ƒ51I.0410.10**28ä.472.98**225j.9248.41**922Û.13192.53**GroupB8ƒ28I.403.84**33ä.863.63**189j.3135.80**702Û.11161.42**GroupC8ƒ6I.922.4342ä.562.73109j.4016.09123Û.0563.25**P0.01,vsgroupC;P0.05,P0.01,vsgroupA25Tab2Serumcontentofcytokinesineachgrouponthefifthexperimentday(xs)GroupNTNF-(ng/L)IL-2(ng/L)IL-6(g/L)IL-8(g/L)GroupA8ƒ48I.6310.52**25ä.944.01**184j.1060.91**982Û.80149.56**GroupB8ƒ29I.703.51**32ä.874.08**166j.7066.61**820Û.10173.91**GroupC8ƒ5I.762.2045ä.763.4577j.409.06117Û.1044.64**P0.01,vsgroupC;P0.05,P0.01,vsgroupA33Tab3Serumcontentofinflammatorymediatorsineachgrouponthethirdexperimentday(xs)GroupnNO(mol/L)CRP(mg/L)GroupA6Ð130Þ.1030.85**1520q.0217.0**GroupB6Ð98Þ.4016.38**1208q.0242.0**GroupC6Ð16Þ.006.312q.00.3**P0.01,vsgroupC;P0.05,vsgroupA45Tab4Serumcontentofinflammatorymediatorsineachgrouponthefifthexperimentday(xs)GroupnNO(mol/L)CRP(mg/L)GroupA6Ñ232ß.5087.42**1309r.0171.0**GroupB6Ñ180ß.2085.76**933r.0167.0**GroupC7Ñ17ß.705.162r.00.4**P0.01,vsgroupC;P0.01,vsgroupA2.3BA,,(P0.01);BC(P0.05)52.43(mesentericlymphnode,MLN),CAB(P0.01),BA,(P0.01),653Tab5Serumcontentofendotoxinineachgrouponthethirdexperimentday(xs,EU/ml)GroupnEndotoxinGroupA10v0Ý.410.14GroupB10v0Ý.210.08**GroupC10v0Ý.080.03**P0.01,vsgroupA3122005533JChinIntegrMed,May2005,Vol.3,No.363Tab6Numbersoftranslocatedbacteriainliver,spleenandmesentericlymphnodesineachgrouponthethirdexperimentday(xs,cfu/0.1ml)GroupnLiverSpleenMLNGroupA10 61s.604.45**28�.206.16**36Ç.808.92**GroupB10 13s.808.92**14�.202.10**16Ç.701.77**GroupC10 2s.401.842�.302.004Ç.202.82**P0.01,vsgroupC;P0.01,vsgroupA33.1,,,,,,,,,,,,,,,,,,,,,,(),,--,,,,,3.2,S-IgA,,[2,3],,,[46],,,,,,,,3.3,,,[7]IL-2T,BIL-2[8]3CIL-2,A,B,IL-2A,IL-6B,,,IL-1B,,,3AIL-6,BA,IL-6IL-8,4122005533JChinIntegrMed,May2005,Vol.3,No.3,3,AIL-8,B,5AIL-8,B,IL-8TNF-,ATNF-,B,TNF-IL-8CRP,CRP,CRP,,CRPNO,,,,,NONO,,NO,NO[]1,,.[J].,2002,16(3):42-43.2,.[J].,1991,8(3):115-116.3.[J].,1994,15(3):135-139.4,,.24[J].,2004,45(2):127-128.5,.-[J].,1989,9(3):144-147.6,.[M].:,1978.416-423.7FongY,MoldawerLL,ShiresGT,etal.Thebiologiccharacteristicsofcytokinesandtheirimplicationinsurgicalinjury[J].SurgGynecolObstet,1990,170(4):363-378.8.-2[J].,1991,8(4):145-149.[]2005-04-01[]2005,,,,,2005102005,1.:(1);(2);(3);(4);(5);(6);(7);(8);(9);(10);(11);(12);(13)2.:,,,,E-mail,WordA41,